Table 1.
Selected patient characteristics comparing continuers to discontinuers of each atypical antipsychotic medication, weighted by propensity score
| Group Na | Aripiprazole | Ziprasidone | Quetiapine | Risperidone | Olanzapine | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Cont. 416 % |
Disc.1421 % |
Cont. 140 % |
Disc. 431 % |
Cont. 1542 % |
Disc. 2951 % |
Cont. 343 % |
Disc. 1449 % |
Cont. 375 % |
Disc. 978 % |
|
| Age and race | ||||||||||
| Mean age (SD)b | 24.8 (7.2) | 24.4 (6.7) | 25.0 (6.4) | 25.0 (5.4) | 26.8 (6.4) | 26.5 (6.3) | 25.3 (7.4) | 25.5 (7.5) | 28.5 (6.9) | 27.1 (6.4) |
| White | 66.6 | 68.6 | 67.9 | 68.2 | 72.4 | 72.5 | 49.3 | 50.3 | 51.2 | 52.6 |
| Black | 19.7 | 19.2 | 20.7 | 21.0 | 15.4 | 16.0 | 30.3 | 30.9 | 24.5 | 23.4 |
| Other race | 13.7 | 12.3 | 11.4 | 10.8 | 12.1 | 11.5 | 20.4 | 18.8 | 24.3 | 24.1 |
| Mental health diagnosis | ||||||||||
| ADHD | 9.4 | 9.2 | 10.7 | 10.0 | 8.3 | 8.3 | 14.9 | 15.0 | 4.5 | 5.3 |
| Bipolar disorder | 44.5 | 45.0 | 44.3 | 45.2 | 35.9 | 35.3 | 25.1 | 25.6 | 31.7 | 41.9 |
| Schizophrenia/Other psychoses | 10.1 | 10.7 | 17.1 | 17.8 | 7.4 | 8.2 | 17.8 | 18.7 | 22.9 | 24.1 |
| Depression | 39.2 | 38.0 | 41.4 | 39.8 | 42.9 | 43.7 | 44.3 | 45.6 | 38.7 | 39.3 |
| Anxiety disorder | 24.8 | 25.9 | 22.1 | 22.6 | 28.7 | 29.5 | 19.8 | 19.3 | 20.8 | 24.1 |
| Comorbidity and other psychotropic use | ||||||||||
| Prior GDMc | 4.8 | 4.7 | 2.1 | 1.6 | 4.9 | 5.2 | 3.2 | 2.8 | 2.9 | 1.5 |
| Obesity | 5.3 | 4.6 | 3.6 | 4.5 | 2.3 | 2.2 | 2.3 | 1.7 | 2.4 | 0.7 |
| Antidepressants | 71.6 | 71.8 | 73.6 | 72.4 | 75.6 | 75.5 | 72.6 | 72.2 | 70.7 | 71.2 |
| Benzodiazepines | 33.7 | 35.2 | 39.3 | 40.5 | 39.4 | 38.9 | 23.6 | 24.7 | 29.1 | 31.3 |
| Mood stabilizersd | 29.6 | 28.9 | 31.4 | 35.4 | 31.8 | 31.3 | 28.6 | 32.1 | 21.3 | 26.5 |
| Opioids | 35.8 | 38.1 | 40.7 | 40.3 | 46.7 | 47.1 | 27.4 | 27.7 | 32.8 | 34.1 |
| Antipsychotic use in 90 days before LMP | ||||||||||
| Exposed ≤30 days | 20.2 | 20.0 | 18.6 | 17.3 | 19.3 | 19.3 | 27.7 | 28.0 | 20.5 | 21.0 |
| Exposed >30 days, ≤60 days | 30.8 | 31.2 | 23.6 | 25.8 | 20.2 | 20.4 | 28.9 | 29.9 | 25.9 | 23.6 |
| Exposed >60 days | 49.0 | 48.8 | 57.9 | 56.9 | 60.5 | 60.2 | 43.4 | 42.1 | 53.6 | 55.4 |
Number of subject in each group after trimming and stratification
Age was categorized in propensity score models but presented with the mean in this table for simplicity
The presence of a diagnosis of GDM in a previous pregnancy was assessed based on all available data before the start of the index pregnancy
Mood stabilizers: Lithium, Carbamazepine, divalproex, lamotrigine, oxcarbazepine, topiramate, valproic acid, valproate sodium
Bolded cells: Absolute Standardized difference > 0.1 after propensity score weighting.
Cont: Continuers; Disc: Discontinuers; SD: standard deviation; ADHD: attention-deficit hyperactivity disorder; GDM: gestational diabetes; LMP: last menstrual period